Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial
Lotte Kjærsgaard, Jonas Wiedemann, Wolfgang Singer, Atsushi Takeda et autres
5 citationsThe Lancet Neurology